Briacell Therapeutics's Customers Performance

Name: Briacell Therapeutics Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

BCTX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


BCTX's Source of Revenues		• List of BCTX Customers

for the same period Briacell Therapeutics Corp

• List of BCTX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Briacell Therapeutics's Comment on Sales, Marketing and Customers

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company is conducting a Phase 3 study of its Bria-IMT™ targeted immunotherapy in combination with the immune checkpoint inhibitor Retifanlimab for metastatic breast cancer. Bria-IMT™ has received Fast Track Designation from the FDA. The company reported improved patient survival in metastatic breast cancer patients treated with Bria-IMT™ and Retifanlimab compared to literature benchmarks.

News about Briacell Therapeutics Corp Contracts

BriaCell Therapeutics Charting a Bold Course in the Battle Against Metastatic Breast Cancer in Phase 3 Trials,

Navigating New Frontiers in Metastatic Breast Cancer: BriaCell s Pioneering Phase 3 Clinical UpdateIn a transformative moment for oncological therapeutics, BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW; TSX: BCT) has announced a significant clinical engagement update regarding its pivotal Phase 3 study involving Bria-IMT, an innovative immunotherapy designed for patients battling metastatic breast cancer (MBC). This announcement, made on October 15, 2024, marks a critical juncture in the company s ongoing mission to redefine cancer care through advanced immunological strategies.The Phase 3 study aims to enroll up to 354 patients, who will be randomly assigned in a 1:1 ratio to receive either the BriaCell...

Briacell Therapeutics’s Comment on Sales, Marketing and Customers

BCTX's Stock Performance relative to it's Customers

BCTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Briacell Therapeutics Corp	26.39	0.00	-30.98	22
SUBTOTAL	0.00	0.00	0.00	-

Sources: Briacell Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Briacell Therapeutics Corp’s corporate clients.
For your research, we’ve provided 9 tables on Briacell Therapeutics Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.